Blog
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
CMS shelves the Medicare Part D portion of the BALANCE model after major insurers decline, extending the temporary Bridge program through 2027 at $50/month copays.
The DoseFDA grants Apotex first tentative approval for generic semaglutide injection, potentially cutting Ozempic costs by 40-60% once patent barriers clear.
The DoseNovo Nordisk's oral Wegovy becomes the first FDA-approved GLP-1 pill for weight loss, launching January 2026 at $149/month—offering 16.6% average weight loss without injections.
The DoseTeva's generic liraglutide (Saxenda) is the first FDA-approved generic GLP-1 indicated for weight loss, approved August 28, 2025. Here is what it means for access, coverage, and cost.
The DoseStanford researchers found that an existing FDA-approved drug could prevent muscle loss during GLP-1 treatment while maintaining fat loss.
The DosePublic has until June 30 to comment on an FDA proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from 503B bulk compounding, which could narrow affordable $150-300 alternatives.
The DoseMedicare's groundbreaking GLP-1 Bridge program starts July 1, 2026, offering Wegovy, Zepbound, and Foundayo for just $50 per month to eligible beneficiaries—marking the first time Medicare covers obesity medications.
The DoseFDA sought public feedback on the Priority Voucher program that enabled the record 50-day approval of Eli Lilly's GLP-1 pill Foundayo.
The DoseEli Lilly's triple-hormone retatrutide delivered up to 28.3% average weight loss in 2,339 patients, with 45% losing 30%+ body weight - surpassing all existing obesity medications.
The DoseFDA proposes to permanently exclude semaglutide, tirzepatide, and liraglutide from 503B bulk compounding, potentially ending $150-300/month alternatives to $1000+ brand drugs.
The DoseMajor Lancet study reveals weekly semaglutide significantly reduced heavy drinking days in adults with alcohol use disorder and obesity.
